COMMUNIQUÉS West-GlobeNewswire

BrightSpring Health Services, Inc. to Host Investor Day on March 17, 2026
17/02/2026
LOUISVILLE, Ky., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it will host an Investor Day on Tuesday, March 17, 2026 [...]
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
17/02/2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
17/02/2026
CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Prenetics Appoints Renowned Longevity Expert and Health-Tech CEO, Dr. Darshan Shah, to Board of Directors
17/02/2026
Appointment Strengthens Board with Deep Clinical and Commercial Expertise in Healthspan Optimization, Aligning with IM8 Growth Strategy NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE [...]
Kyntra Bio to Participate in Upcoming Investor Conferences
17/02/2026
SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
17/02/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 17 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
17/02/2026
MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) [...]
Voting Rights and Shares Capital of the Company
17/02/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
18/02/2026
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
17/02/2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its [...]
Portsmouth Square, Inc. Reports Second Quarter Fiscal 2026 Results; Hotel Performance Improves Year-Over-Year as Market Stabilization Continues
17/02/2026
Los Angeles, California, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the “Company” or “Portsmouth”) today announced financial results for the fiscal second quarter ended December 31, 2025. Portsmouth’s [...]
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
17/02/2026
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, [...]
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
17/02/2026
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic [...]
Clover Health to Participate in Upcoming Leerink 2026 Global Healthcare Conference
17/02/2026
WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will [...]
PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026
17/02/2026
MINNEAPOLIS, MN, US, Feb. 17, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), and its wholly owned subsidiaries PetVivo Animal Health and PetVivo AI, a leading biomedical company delivering [...]
Genmab Announces Initiation of Share Buy-Back Program
17/02/2026
Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no later than March 31 [...]
Fortrea renforce son équipe de direction en nommant Oren Cohen au poste de directeur médical et Scott Dove à celui de président des services de pharmacologie clinique
17/02/2026
Cette évolution vient renforcer l’engagement de la direction en faveur du développement clinique précoce et approfondit son partenariat médical et scientifique avec ses clients DURHAM, Caroline du Nord, 17 févr. 2026 ( [...]
HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics
17/02/2026
Announces earnings date and upcoming investor conferences DRAPER, Utah, Feb. 17, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation's largest health savings account [...]
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
17/02/2026
Media Release COPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB ) a nnounced today that it has filed its Annual Report for the financial [...]

Pages